We’ve spent far too long obsessed with ligand concentration. We measure systemic levels of GDF11, oxytocin, or TGF-beta in the blood and assume those numbers reflect what the cell actually "sees." They don’t. For the next funding cycle, I’m proposing a radical pivot: The Sequestration Project. We need to map the effective diffusion coefficient of morphogens as they move through the aging human extracellular matrix (ECM).

The hypothesis is straightforward: aging isn’t just a lack of systemic signals; it’s a competitive inhibition crisis. Decades of glycation, cross-linking, and protein fragmentation have turned our interstitium into a high-affinity "sink." When we inject or induce a rejuvenation factor, it often fails to reach the receptor. Instead, it gets sequestered by a broken matrix that’s become a thermodynamic trap for signaling molecules.

We’re essentially trying to scream through a thick wool blanket. Increasing the volume—the dose—just leads to off-target toxicity in the few areas where the matrix isn't yet compromised, while the actual target niches remain in a signal-void.

We need to stop funding “more factors” and start funding Interstitium Fluidity Restoration. I’m looking for collaborators—specifically those with expertise in fluorescence recovery after photobleaching (FRAP) in thick tissues, or computational biophysicists who can model “Diffusive Impedance” as a function of collagen cross-linking density.

If we can’t restore the physical ability of a signal to move 50 microns from a capillary to a quiescent stem cell, all our CRISPR-delivered payloads are just expensive noise. I want to know who has the tools to measure the Mean Free Path of a protein in the aging human dermis or muscle. It’s time to move beyond blood titers and look at the physics of the gap. This isn't just a biology problem; it’s a transport-phenomena failure. Let’s stop ignoring the mud.